Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00648739
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:23.202514+00:00
Published At
2019-03-05T00:00:00+00:00
Record Updated At
2019-03-05
Results Posted At
2019-03-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["B-cell Chronic Lymphocytic Leukemia", "Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-03-05"
protocolSection.identificationModule.nctId
"NCT00648739"
protocolSection.identificationModule.officialTitle
"A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-03-05"

Study condition terms

  • B-cell Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.